Praxis Precision Medicines (NASDAQ:PRAX) is a clinical-stage biopharmaceutical company dedicated to discovering and developing precision medicines for patients with severe neurological and neuropsychiatric disorders. The company leverages a proprietary platform that integrates genetics, neurobiology and ion channel research to identify novel targets and tailor therapies to specific neural circuits. By focusing on the molecular underpinnings of conditions such as major depressive disorder, epilepsy and movement disorders, Praxis aims to advance treatments that offer improved efficacy and safety profiles compared with currently available options.
The company’s pipeline features several lead programs in various stages of clinical development. PRAX-114, a selective GABAA receptor positive allosteric modulator, is being investigated for treatment-resistant major depressive disorder and neurodevelopmental indications, while PRAX-944, a small molecule targeting T-type calcium channels, is in trials for essential tremor and related motor disorders. In addition, Praxis is exploring precision ion channel modulators for rare epilepsies, leveraging biomarker-driven approaches to enhance patient selection and optimize therapeutic outcomes.
Founded in 2018 and headquartered in Boston, Massachusetts, Praxis Precision Medicines completed its initial public offering in October 2020 to support the expansion of its research and development efforts. The company’s operations span North America and Europe, where it collaborates with academic institutions, patient advocacy groups and clinical research organizations to accelerate program timelines and broaden access to clinical studies. These partnerships reinforce Praxis’s commitment to translating cutting-edge science into meaningful therapies for underserved patient populations.
Praxis is led by a management team with deep expertise in neuroscience drug discovery and development. The executive group includes biopharmaceutical veterans with track records at both large pharmaceutical companies and pioneering biotech firms, alongside scientific founders who have contributed to seminal research in ion channel physiology. Together, the leadership team is focused on executing a precision-medicine strategy that aims to deliver new treatment options for patients living with complex neurological diseases.
